ORPP logo
Image from Google Jackets

Magnesium and Pyridoxine : Fundamental Studies and Clinical Practice.

By: Material type: TextTextPublisher: New York : Nova Science Publishers, Incorporated, 2009Copyright date: ©2020Edition: 1st edDescription: 1 online resource (213 pages)Content type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781617285332
Subject(s): Genre/Form: Additional physical formats: Print version:: Magnesium and Pyridoxine: Fundamental Studies and Clinical PracticeDDC classification:
  • 612.3/924
LOC classification:
  • QP535.M4 T67 2009
Online resources:
Contents:
Intro -- MAGNESIUM AND PYRIDOXINE:FUNDAMENTAL STUDIESAND CLINICAL PRACTICE -- MAGNESIUM AND PYRIDOXINE:FUNDAMENTAL STUDIESAND CLINICAL PRACTICE -- CONTENTS -- FOREWORD -- INTRODUCTION -- GEOGRAPHIC -- HISTOLOGICAL -- BIOCHEMICAL AND CLINICAL -- CLINICAL -- Chapter 11. THE BIOLOGICAL ROLES OF MAGNESIUM -- 1.1. BACKGROUND -- 1.2. EPIDEMIOLOGY -- 1.3. BIOLOGICAL ROLES OF MAGNESIUM -- Chapter 22. ABSORPTION, ELIMINATION AND THE DAILYREQUIREMENT OF MAGNESIUM -- Chapter 33. THE DEFICIENCY OF MAGNESIUM -- 3.1. ETIOLOGY OF MAGNESIUM DEFICIENCY -- 3.2. PRIMARY AND SECONDARYMAGNESIUM DEFICIENCY -- 3.3. CLINICAL SYMPTOMSOF MAGNESIUM DEFICIENCY -- 3.4. CONSEQUENCES OF MAGNESIUM DEFICIENCY -- Chapter 44. CONDITIONS AND DISEASES ACCOMPANIEDBY MAGNESIUM DEFICIENCY -- 4. 1. MAGNESIUM AND PREGNANCY -- 4.1.1. Hypomagnesemia and condition of the fetus -- 4.1.2. Glucose Tolerance, Metabolic Syndrome, Gestational Diabetes -- 4.1.3. Recurrent Pregnancy Loss -- 4.1.4. Pre-Eclampsia, Eclampsia and Magnesium Sulphate Therapy -- 4.1.5. Hypermagnesemia in Pregnancy -- 4.2. MAGNESIUM AND PYRIDOXINE IN PREMENSTRUAL SYNDROME -- INFLUENCE OF THE STEROID-BASED DRUGS -- 4.3. MAGNESIUM DEFICIENCY AND PATHOLOGIESOF THE CENTRAL NERVOUS SYSTEM -- 4.3.1. Neuromuscular Manifestations -- 4.3.2. Stress, Chronic Fatigue Syndrome and Vegetative Dystonia -- 4.3.3. Magnesium and Neurodegenerative Diseases -- 4.3.4. Magnesium and Diseases of Dependence(Alcohol, Narcotic and Nicotine Dependence) -- 4.4. MAGNESIUM AND CARDIOLOGY -- 4.4.1. Molecular Effects of the Magnesiumon the Biochemistry of the Cardiac Tissue -- 4.4.2. Magnesium and Myocardial Infarction (MI) -- 4.4.3. Magnesium and Arrhythmia -- 4.4.4. Magnesium and Arterial Hypertension -- 4.4.5. Magnesium and Atherosclerosis -- 4.4.6. Magnesium and Thrombus Formation -- Magnesium and Thromboxane Synthesis -- Magnesium and Coagulation.
Magnesium and Inflammation of Vascular Endothelium -- 4.5. MAGNESIUM AND UROLOGY -- 4.6. MAGNESIUM AND DIABETES -- 4.7. MAGNESIUM AND PATHOLOGIES OF THE CONNECTIVE TISSUE -- 4.7.1. Undifferentiated Connective Tissue Dysplasias -- 4.7.2. Magnesium and Molecular Cell Biology of the Connective Tissue -- 4.7.3. Magnesium and Disorders of Skeletal System -- 4.8. MAGNESIUM AND BRONCHIAL OBSTRUCTION -- 4.9. MAGNESIUM AND PYRIDOXINE:IMMUNITY, ONCOLOGY AND TRANSPLANTATION -- 4.10. MAGNESIUM AND PROFESSIONAL PATHOLOGIES -- 4.10.1. Cadmium and Magnesium -- 4.10.2. Beryllium and Magnesium -- 4.10.3. Aluminium and Magnesium -- 4.10.4. Lead and Magnesium -- 4.10.5. Nickel and Magnesium -- 4.10.6. Radiation and Magnesium -- 4.11. MAGNESIUM AND SPORTS -- Chapter 55. CORRECTION OF THE MAGNESIUM DEFICIT -- 5.1. MAGNESIUM DIET -- 5.2. SOURCES OF MAGNESIUM IN THE ENVIRONMENT -- 5.3. PHARMACOLOGICAL CORRECTION OF MAGNESIUM DEFICIENCY -- 5.4. PARENTERAL MAGNESIUM THERAPY -- 5.5. MAGNESIUM-PRESERVING DIURETICS -- 5.6. MAGNESIUM FIXATION -- Chapter 66. EFFECTS OF VARIOUS DRUGSON MAGNESIUM HOMEOSTASIS -- 6.1. PARTIAL MAGNESIUM ANALOGUES -- 6.2. MAGNESIUM PROTECTORS -- 6.3. MAGNESIUM-DEPLETING DRUGS -- Chapter 77. TOXICOLOGY OF MAGNESIUM:HYPERMAGNESEMIA -- Chapter 88. PHYSIOLOGICAL IMPORTANCE OF PYRIDOXINE -- 8.1. METABOLISM, ABSORPTION AND ELIMINATION OF PYRIDOXINE -- 8.2. PYRIDOXINE DEFICIENCY -- 8.3. DIETARY PYRIDOXINE REQUIREMENTS -- 8.4. TREATMENT OF PYRIDOXINE DEFICIENCY -- Chapter 99. DETERMINATION OF THE MAGNESIUMAND PYRIDOXINE LEVELS -- 9.1. THE MAJOR METHODS FOR DETERMINATIONOF THE MAGNESIUM DEFICIENCY -- 9.2. ADDITIONAL METHODS FOR DETERMININGTHE MAGNESIUM DEFICIENCY -- 9.3. DETERMINATION OF PYRIDOXINE -- CONCLUSION -- APPENDIX I. THE CONTENTS OF MINERALSUBSTANCES AND PYRIDOXINE IN DIFFERENT FOODS.
APPENDIX II. REFERENCE VALUES OF MINERALAND TRIGLYCERIDE LEVELS (GROMOVA, 2001) -- APPENDIX III. TESTING GLYCOSYLATEDHEMOGLOBIN-C (HBA1C) -- APPENDIX IV. GENES IMPLICATEDIN MAGNESIUM HOMEOSTASIS -- APPENDIX V. POLYMORPHISMS ASSOCIATEDWITH CONNECTIVE TISSUE DISPLASIAS (CTD) -- APPENDIX VI. MAGNE-B6 FILM-COATED TABLETS -- COMPOSITION -- PHARMACOLOGICAL ACTION -- INDICATIONS -- DOSAGE -- SIDE EFFECTS -- CONTRAINDICATIONS -- SPECIAL PRECAUTIONS -- DRUG-DRUG INTERACTIONS -- OVERDOSE -- REFERENCES -- INDEX -- Blank Page -- Blank Page.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
No physical items for this record

Intro -- MAGNESIUM AND PYRIDOXINE:FUNDAMENTAL STUDIESAND CLINICAL PRACTICE -- MAGNESIUM AND PYRIDOXINE:FUNDAMENTAL STUDIESAND CLINICAL PRACTICE -- CONTENTS -- FOREWORD -- INTRODUCTION -- GEOGRAPHIC -- HISTOLOGICAL -- BIOCHEMICAL AND CLINICAL -- CLINICAL -- Chapter 11. THE BIOLOGICAL ROLES OF MAGNESIUM -- 1.1. BACKGROUND -- 1.2. EPIDEMIOLOGY -- 1.3. BIOLOGICAL ROLES OF MAGNESIUM -- Chapter 22. ABSORPTION, ELIMINATION AND THE DAILYREQUIREMENT OF MAGNESIUM -- Chapter 33. THE DEFICIENCY OF MAGNESIUM -- 3.1. ETIOLOGY OF MAGNESIUM DEFICIENCY -- 3.2. PRIMARY AND SECONDARYMAGNESIUM DEFICIENCY -- 3.3. CLINICAL SYMPTOMSOF MAGNESIUM DEFICIENCY -- 3.4. CONSEQUENCES OF MAGNESIUM DEFICIENCY -- Chapter 44. CONDITIONS AND DISEASES ACCOMPANIEDBY MAGNESIUM DEFICIENCY -- 4. 1. MAGNESIUM AND PREGNANCY -- 4.1.1. Hypomagnesemia and condition of the fetus -- 4.1.2. Glucose Tolerance, Metabolic Syndrome, Gestational Diabetes -- 4.1.3. Recurrent Pregnancy Loss -- 4.1.4. Pre-Eclampsia, Eclampsia and Magnesium Sulphate Therapy -- 4.1.5. Hypermagnesemia in Pregnancy -- 4.2. MAGNESIUM AND PYRIDOXINE IN PREMENSTRUAL SYNDROME -- INFLUENCE OF THE STEROID-BASED DRUGS -- 4.3. MAGNESIUM DEFICIENCY AND PATHOLOGIESOF THE CENTRAL NERVOUS SYSTEM -- 4.3.1. Neuromuscular Manifestations -- 4.3.2. Stress, Chronic Fatigue Syndrome and Vegetative Dystonia -- 4.3.3. Magnesium and Neurodegenerative Diseases -- 4.3.4. Magnesium and Diseases of Dependence(Alcohol, Narcotic and Nicotine Dependence) -- 4.4. MAGNESIUM AND CARDIOLOGY -- 4.4.1. Molecular Effects of the Magnesiumon the Biochemistry of the Cardiac Tissue -- 4.4.2. Magnesium and Myocardial Infarction (MI) -- 4.4.3. Magnesium and Arrhythmia -- 4.4.4. Magnesium and Arterial Hypertension -- 4.4.5. Magnesium and Atherosclerosis -- 4.4.6. Magnesium and Thrombus Formation -- Magnesium and Thromboxane Synthesis -- Magnesium and Coagulation.

Magnesium and Inflammation of Vascular Endothelium -- 4.5. MAGNESIUM AND UROLOGY -- 4.6. MAGNESIUM AND DIABETES -- 4.7. MAGNESIUM AND PATHOLOGIES OF THE CONNECTIVE TISSUE -- 4.7.1. Undifferentiated Connective Tissue Dysplasias -- 4.7.2. Magnesium and Molecular Cell Biology of the Connective Tissue -- 4.7.3. Magnesium and Disorders of Skeletal System -- 4.8. MAGNESIUM AND BRONCHIAL OBSTRUCTION -- 4.9. MAGNESIUM AND PYRIDOXINE:IMMUNITY, ONCOLOGY AND TRANSPLANTATION -- 4.10. MAGNESIUM AND PROFESSIONAL PATHOLOGIES -- 4.10.1. Cadmium and Magnesium -- 4.10.2. Beryllium and Magnesium -- 4.10.3. Aluminium and Magnesium -- 4.10.4. Lead and Magnesium -- 4.10.5. Nickel and Magnesium -- 4.10.6. Radiation and Magnesium -- 4.11. MAGNESIUM AND SPORTS -- Chapter 55. CORRECTION OF THE MAGNESIUM DEFICIT -- 5.1. MAGNESIUM DIET -- 5.2. SOURCES OF MAGNESIUM IN THE ENVIRONMENT -- 5.3. PHARMACOLOGICAL CORRECTION OF MAGNESIUM DEFICIENCY -- 5.4. PARENTERAL MAGNESIUM THERAPY -- 5.5. MAGNESIUM-PRESERVING DIURETICS -- 5.6. MAGNESIUM FIXATION -- Chapter 66. EFFECTS OF VARIOUS DRUGSON MAGNESIUM HOMEOSTASIS -- 6.1. PARTIAL MAGNESIUM ANALOGUES -- 6.2. MAGNESIUM PROTECTORS -- 6.3. MAGNESIUM-DEPLETING DRUGS -- Chapter 77. TOXICOLOGY OF MAGNESIUM:HYPERMAGNESEMIA -- Chapter 88. PHYSIOLOGICAL IMPORTANCE OF PYRIDOXINE -- 8.1. METABOLISM, ABSORPTION AND ELIMINATION OF PYRIDOXINE -- 8.2. PYRIDOXINE DEFICIENCY -- 8.3. DIETARY PYRIDOXINE REQUIREMENTS -- 8.4. TREATMENT OF PYRIDOXINE DEFICIENCY -- Chapter 99. DETERMINATION OF THE MAGNESIUMAND PYRIDOXINE LEVELS -- 9.1. THE MAJOR METHODS FOR DETERMINATIONOF THE MAGNESIUM DEFICIENCY -- 9.2. ADDITIONAL METHODS FOR DETERMININGTHE MAGNESIUM DEFICIENCY -- 9.3. DETERMINATION OF PYRIDOXINE -- CONCLUSION -- APPENDIX I. THE CONTENTS OF MINERALSUBSTANCES AND PYRIDOXINE IN DIFFERENT FOODS.

APPENDIX II. REFERENCE VALUES OF MINERALAND TRIGLYCERIDE LEVELS (GROMOVA, 2001) -- APPENDIX III. TESTING GLYCOSYLATEDHEMOGLOBIN-C (HBA1C) -- APPENDIX IV. GENES IMPLICATEDIN MAGNESIUM HOMEOSTASIS -- APPENDIX V. POLYMORPHISMS ASSOCIATEDWITH CONNECTIVE TISSUE DISPLASIAS (CTD) -- APPENDIX VI. MAGNE-B6 FILM-COATED TABLETS -- COMPOSITION -- PHARMACOLOGICAL ACTION -- INDICATIONS -- DOSAGE -- SIDE EFFECTS -- CONTRAINDICATIONS -- SPECIAL PRECAUTIONS -- DRUG-DRUG INTERACTIONS -- OVERDOSE -- REFERENCES -- INDEX -- Blank Page -- Blank Page.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.

There are no comments on this title.

to post a comment.

© 2024 Resource Centre. All rights reserved.